Our leadership combines decades of clinical expertise, operational excellence, and scientific rigor to deliver transformative care.
Founder & CEO of BetterStem
Greice Murphy founded BetterStem not to be just another company offering stem cell therapy—but to fundamentally change how autism is approached in the United States.
For Greice, BetterStem is more than a business. It is a mission—and a human responsibility. A responsibility to challenge outdated systems, advocate for change, and make safe, effective, science-driven treatments accessible to families who urgently need options yet are too often left without them.
With more than two decades of leadership in healthcare, Greice brings a rare combination of vision, operational execution, financing expertise, and patient-centric decision-making. Her work consistently bridges the gap between innovation and real-world delivery—ensuring care models are not only advanced, but scalable, compliant, and accountable.
Before BetterStem, Greice founded and scaled Advanced Care Partners, a multi-state home healthcare organization serving medically fragile children. Under her leadership, ACP expanded across several states, partnered closely with pediatric hospitals and Medicaid programs, influenced waiver policy, and ultimately achieved a successful strategic exit. That experience reinforced her conviction that systems must change—not just treatments—for lives to truly improve.
At BetterStem, Greice has assembled a team of forward-thinking leaders, physicians, scientists, regulatory experts, and operators—real people who genuinely care and are deeply passionate about the mission. Together, they are building a paradigm shift in autism care—designed to transform lives, empower families, and set a new global standard for regenerative therapies in neurodevelopmental disorders.
Greice's commitment to vulnerable children extends beyond healthcare. She serves on the board of the Orphaned Starfish Foundation, which builds technology schools for orphans in 32 countries, and on the board of Extra Special People, supporting children with disabilities and their families through inclusive community programs.
Across everything she builds, Greice is guided by one principle: innovation without responsibility is meaningless. Through BetterStem and her broader work, she continues to advocate for safer systems, smarter access, and care models that genuinely transform the lives they touch.
Medical Director of BetterStem
Dr. Atul Vats serves as the Medical Director of BetterStem, bringing more than 25 years of clinical and leadership experience in pediatric and critical care medicine to the forefront of regenerative therapy and ASD biology.
Board-certified in Pediatrics and Pediatric Critical Care Medicine, Dr. Vats is a seasoned physician-leader committed to advancing patient-centered care through rigorous science, ethical oversight, and compassionate clinical practice.
Dr. Vats began his medical journey at the University of Kansas School of Medicine, where he earned his M.D. and completed his pediatric internship and residency. He went on to become a founding fellow in Pediatric Critical Care Medicine at Emory University School of Medicine, one of the nation's leading centers for complex pediatric care.
Later, he expanded his expertise by earning a Master of Business Administration from Emory's Goizueta Business School, equipping him with strategic and operational insight into clinical program leadership.
Throughout his career, Dr. Vats has led teams in high-acuity environments, focusing on systems of care that support the most vulnerable patients. His leadership extends beyond the bedside — he has held medical directorships and played key roles in shaping clinical standards, mentoring physicians, and driving quality improvement across healthcare systems.
At BetterStem, Dr. Vats blends his depth of clinical experience with a passion for regenerative medicine and innovative therapeutic pathways. As Medical Director, he helps ensure that protocols — including those involving stem cells under Right to Try and IRB-approved frameworks — are grounded in the latest scientific understanding, ethical oversight, and patient safety principles.
He champions an integrated, 360° approach to ASD care, where biological systems such as the gut-brain axis, immune function, and neural inflammation are evaluated together rather than in isolation.
Dr. Vats's leadership reflects a belief that advancing care for complex conditions like autism requires both cutting-edge science and a deep respect for the lived experience of families. He is dedicated to fostering outcomes-focused care that aligns with BetterStem's mission to expand access to regenerative options backed by science, oversight, and real-world understanding.
Co-Founder & Chief Operating Officer of BetterStem
Remco Bos is the Co-Founder and Chief Operating Officer of BetterStem, where he drives operational excellence, strategic growth, and a patient-centric culture across the organization.
With a career built on transforming visionary ideas into operational reality, Remco blends deep strategic insight with a relentless focus on execution. He oversees BetterStem's day-to-day operations, ensuring that our clinical, regulatory, and administrative systems work together seamlessly.
Remco's leadership philosophy centers on creating scalable, ethical, and outcomes-focused systems. He champions cross-disciplinary collaboration and data-driven process design to ensure that every family who comes to BetterStem experiences care that is safe, transparent, and thoughtfully delivered.
Remco is committed to advancing scientifically validated, data-driven regenerative medicine, where innovation is held to the same standards as execution. He believes regenerative therapies must be grounded in measurable outcomes, rigorous oversight, and real-world clinical data. His work ensures that BetterStem delivers on its promise: access to transformative compliant care, grounded in science, with accountability at every level.
Board Advisor at BetterStem
Dr. Barbara Krutchkoff is an internationally respected expert in regenerative and cellular medicine and serves as a valued Board Advisor at BetterStem. With more than 25 years of hands-on experience in translational medicine, clinical research design, regulatory strategy, and ethical oversight, Dr. Krutchkoff brings deep scientific credibility and practical wisdom to our mission.
Dr. Krutchkoff is the Executive Director of the Institute for Regenerative and Cellular Medicine (IRCM) and has advised physicians, biotech startups, research institutions, and regulatory bodies on navigating complex clinical and regulatory pathways in regenerative biologics.
She has consulted with clinics and individual practitioners on study design, FDA and IRB interactions, and commercialization strategy — helping to bridge the gap between cutting-edge science and patient access.
Barbara's work is grounded in bringing regenerative medicine safely and ethically to patients, with an emphasis on study validation, clinical oversight, and collaborative research networks that support real-world outcomes.
At BetterStem, she provides high-level strategic guidance on scientific rigor, ethical study design, and responsible integration of regenerative protocols — ensuring that innovation is matched with safety, compliance, and meaningful patient benefit.
Board Advisor, Healthcare Strategy & Digital Innovation
Stephen Bonner is a seasoned healthcare executive and operator with a proven track record of leading growth stage healthcare and digital health companies while advancing patient-centric, technology-enabled care models.
He currently serves as Chief Executive Officer of SkinIO, LLC, an AI-powered preventive health platform transforming access to early skin cancer detection through virtual exams and teledermatology.
At SkinIO, Stephen leads corporate strategy, product innovation, and enterprise partnerships across employers, health plans, and clinical networks. Under his leadership, the company has expanded access to early detection tools, reduced barriers to dermatologic care, and scaled technology that enables faster identification and treatment of skin cancer.
Previously, Stephen served as President and Chief Executive Officer of Cancer Treatment Centers of America (CTCA), where he led the organization for more than a decade. During his tenure, CTCA became nationally recognized for its patient-focused care model, clinical excellence, and consumer transparency in oncology.
His leadership helped position CTCA as a differentiated, outcomes-driven healthcare system during a period of significant industry consolidation and change.
Stephen has served on the boards of healthcare and technology companies, including:
His board experience reflects a deep ability to bridge clinical strategy, consumer health, governance, and growth execution.
In recognition of his impact on the healthcare industry, Stephen has been named one of Modern Healthcare's "100 Most Influential People in Healthcare."
He holds a B.A. from Amherst College and a J.D. from Mitchell Hamline School of Law, bringing a rare combination of operational leadership, healthcare insight, and legal perspective to complex healthcare environments.
At BetterStem, Stephen contributes strategic guidance rooted in real-world execution—helping ensure that breakthrough regenerative therapies are built, governed, and scaled with credibility, discipline, and patient impact at the core.
Board Advisor at BetterStem
Howard B. Urnovitz, Ph.D., is a seasoned biotech leader, molecular biologist, and innovator with over four decades of experience at the intersection of genomics, diagnostics, and translational science. He serves as CEO and Co-Founder of FBB Biomed, a company building next-generation, AI-enhanced genomic blood tests designed to transform early disease detection and monitoring.
Dr. Urnovitz earned his Ph.D. in Microbiology & Immunology from the University of Michigan and completed postdoctoral research in tumor immunology at Washington University and the University of Iowa. Throughout his career, he has led development of groundbreaking diagnostic technologies—including one of the first rapid HIV tests, early liquid biopsies for cancer, and proprietary approaches to decoding endogenous genomic signals tied to chronic disease.
A prolific researcher and inventor, Howard combines deep scientific rigor with entrepreneurial grit, having led multiple companies from early development through commercialization and regulatory approvals. His work spans RNA virology, genomics, AI-driven diagnostics, and molecular biomarkers, anchoring BetterStem's advisory bench with both strategic perspective and cutting-edge scientific insight.
At BetterStem, Howard brings rigorous scientific leadership and platform-level thinking to our autism treatment discovery efforts. His expertise in interpreting complex genomic and transcriptomic signals—especially RNA biomarkers—helps shape how we evaluate biological responses and mechanisms that may underlie neurodevelopmental disorders like autism.
Leveraging this depth of molecular insight allows our clinical science team to refine hypotheses on how regenerative and biological therapies could modulate core pathways in ASD and identify meaningful biomarkers for treatment response.
His visionary work—from launching one of the first FDA-approved diagnostic tests to building tools that uncover patient-specific molecular signatures—complements BetterStem's mission of pushing beyond symptomatic care toward data-informed, mechanism-driven approaches for ASD.
By helping steer research strategy, biomarker integration, and cross-disciplinary scientific review, Howard ensures our developmental pathways are grounded in cutting-edge biology and real translational potential.
Howard B. Urnovitz is an active public voice on genomics and human evolution. In a recent podcast with neurologist Dr. Ken Shalin, he discusses ideas from his book on how industrialization is impacting human genetics.
Watch: The Healthy Brain Toolbox PodcastBeyond his industry leadership, Dr. Urnovitz is committed to advancing biomedical research and discovery—demonstrated by his significant philanthropic contributions to academic virology and immunology programs and his ongoing advocacy for translational science that improves patient outcomes.
Our values shape how we serve families and drive innovation in stem cell therapy for autism.
We operate under FDA-aligned Right-to-Try pathways with full IRB oversight, ethical sourcing standards, and complete transparency for every family we serve.
We deliver real-world outcomes for patients — not promises buried in bureaucracy or stalled by big-pharma politics. Action and accountability drive everything we do.
We stand firmly on the side of parents fighting every day for progress. Your child's needs and your family's goals are at the center of every decision we make.
Our treatments are delivered under the guidance of experienced physicians, academic collaborators, and regulatory experts using clinically aligned protocols.
We eliminate unnecessary barriers and bureaucratic delays. When families need help, speed matters — but never at the expense of safety or integrity.
A portion of our profits is reinvested directly into providing care for underprivileged families who would otherwise have no access to these treatments.
Connect with our team to learn more about BetterStem's FDA-aligned Right-to-Try pathway for stem cell therapy and how we can support your family's journey.